CRI's new website that seeks to engage, educate, and empower patients and their loved ones to learn more about cancer immunotherapy as a treatment option across numerous tumor types.
Cancer patients, donors, scientists, and other supporters all stand behind the Cancer Research Institute. Read their stories and learn about what motivates each of us to keep fighting against cancer.
This June, help us raise awareness of cancer immunotherapy as a revolutionary new treatment for patients today.
We gratefully accept donations made in memory or in honor of a loved one. Your gift will be acknowledged to whomever you specify.
Numerous challenges can derail progress in finding new immune-based cancer treatments. We're solving some of the biggest challenges, keeping promising new immunotherapies on the fast track to patients.
Get the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements.
When the Cancer Research Institute was founded in 1953, we knew then that immune-based treatments would transform cancer medicine. In more than six decades since, we've made numerous groundbreaking discoveries that have given more patients new hope today.
Welcome to the Cancer Research Institute blog. Here we share the latest updates on the field of cancer immunotherapy from CRI, including scientific breakthroughs, news stories, and program announcements. We invite your comments and encourage you to share these stories with your friends.
You can receive notifications of new posts by subscribing to our blog. Just click the RSS icon in the upper right corner.
June 20, 2014
Jill O'Donnell-Tormey, Ph.D.
cancer immunotherapy, clinical accelerator, clinical trials, experimental, innovation
Combining multiple treatments given at the right time and in the right doses is key to optimizing cancer therapy, scientists believe.
clinical accelerator, clinical trial, collaboration, immunotherapy, ludwig institute, pancreatic cancer, ralph steinman, vaccine
Lloyd J. Old, the Father of Modern Tumor Immunology and the founding scientific and medical director of the Cancer Research Institute, succumbed to prostate cancer at the age of 78.
lloyd old, obituary
Whether a patient benefits from a cancer therapy can depend on existing genetic and other conditions within the patient and his or her tumors. Personalized approaches to cancer patient care will help ensure patients receive only those treatments that may benefit them rather than endure hit or miss rounds of potentially debilitating therapy.
herceptin, patient care, personalized medicine, side effects